Qiuwen Biotechnology

Chongqing Qiuwen Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of innovative small molecule targeted therapies for cancer. Founded in 2021 by Dr. Gong Xianchang, a veteran of the US biotech industry, the company focuses on the Hedgehog signaling pathway to treat various malignancies. Its lead candidate, JNSW10032, is a potent SMO receptor antagonist currently in Phase 1 clinical trials for acute myeloid leukemia (AML) and is being explored for solid tumors including lung and pancreatic cancer. Headquartered in Chongqing, China, the company leverages its founder's extensive experience in oncology drug discovery to advance its pipeline of precision medicines. The company's research is supported by regional innovation platforms in the Western (Chongqing) Science City.